Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)

28 oktober 2026 bijgewerkt door: Novartis Pharmaceuticals

Onasemnogene Abeparvovec: Het beoordelen van de veiligheid en effectiviteit in de praktijk van deelnemers met spinale musculaire atrofie die behandeld zijn met intrathecaal Onasemnogene Abeparvovec-brve (ITVISMA®): Een pragmatische multicenterstudie in de VS (STREAM)

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

Studie Overzicht

Toestand

Werving

Gedetailleerde beschrijving

STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.

Studietype

Ingrijpend

Inschrijving (Geschat)

36

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Novartis Pharmaceuticals

Studie Locaties

    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 208833
        • Werving
        • Arkansas Children's Hospital
        • Hoofdonderzoeker:
          • Aravindhan Veerapandiyan
        • Contact:
          • Buffy Gofforth
          • Telefoonnummer: (501) 364-1591
    • California
      • Stanford, California, Verenigde Staten, 94305-5235
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02215
    • New York
      • New York, New York, Verenigde Staten, 10032
        • Werving
        • Columbia University Medical Center
        • Hoofdonderzoeker:
          • Claudia Chiriboga
        • Contact:
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43210
        • Werving
        • Ohio State University Medical Center
        • Hoofdonderzoeker:
          • Bakri Elsheikh
        • Contact:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 209277

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

2 jaar tot 100 jaar (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria:

A participant will be enrolled in STREAM only if all the following conditions are met:

  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).

  • He or she is ≥ 2 years of age on the day of the intrathecal injection.

  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.

  • One of the following functional categories applies at screening:

    1. independently ambulatory child/adolescent 2 - <18 years; or
    2. independently ambulatory adult (≥ 18 years).
    3. non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.

Key Exclusion Criteria:

A participant will be excluded if any of the following conditions apply:

  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.

Other protocol inclusion, exclusion criteria may apply.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Onasemnogene Abeparvovec-brve

Participants with spinal muscular atrophy, including:

  • independently ambulatory children/adolescents (≥ 2 years to < 18 years);
  • independently ambulatory adults (≥ 18 years);
  • Non-ambulatory adults (≥ 18 years)

administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.

Andere namen:
  • (ITVISMA®)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from baseline in HFMSE for independently ambulatory participants
Tijdsspanne: Baseline, 6, 12, 18 and 24 months

The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression.

The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
Tijdsspanne: Baseline, 6, 12, 18 and 24 months

The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: up to 5 years

Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs.

up to 5 years
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
Tijdsspanne: Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5

Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
Tijdsspanne: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
Tijdsspanne: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Subgroup outcomes: Revised Upper Limb Module (RULM)
Tijdsspanne: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Tijdsspanne: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Tijdsspanne: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Cobb angle
Tijdsspanne: Baseline, up to 24 months

Assessment of scoliosis progression as a disease-progression marker.

Baseline, up to 24 months
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
Tijdsspanne: Baseline, up to 24 months

Assessment of respiratory function as a disease-progression marker.

Baseline, up to 24 months
Joint-range limitation measured by goniometer
Tijdsspanne: Baseline, up to 24 months

Assessment of evolution of joint contractures as a disease-progression marker.

Baseline, up to 24 months
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
Tijdsspanne: Baseline, up to 24 months

Assessment of nutrition status as a disease-progression marker.

Baseline, up to 24 months
6-Minute Walk Test (6MWT) for ambulatory patients
Tijdsspanne: Baseline, Months 6, 12, 18, and 24

To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity.

Baseline, Months 6, 12, 18, and 24

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 augustus 2026

Primaire voltooiing (Geschat)

3 mei 2032

Studie voltooiing (Geschat)

30 juni 2032

Studieregistratiedata

Eerst ingediend

26 februari 2026

Eerst ingediend dat voldeed aan de QC-criteria

26 februari 2026

Eerst geplaatst (Werkelijk)

4 maart 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

29 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

28 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren